Why the study?
After the global withdrawal of OPV2, outbreak response use created a cycle of VDPV2 emergences that threaten poliovirus eradication.
What are the risk factors for Serotype-2 Vaccine-Derived Poliovirus emergences following OPV2 campaigns in Africa?
What are the risk factors for Serotype-2 Vaccine-Derived Poliovirus emergences following OPV2 campaigns in Africa?
Answers are grounded in this paper and cite their sources.
Higher population immunity and smaller campaign sizes are associated with a reduced risk of vaccine-derived poliovirus emergences following OPV2 campaigns.
Serotype 2 oral poliovirus vaccine (OPV2) can revert to regain wild-type neurovirulence and spread to cause emergences of vaccine-derived poliovirus (VDPV2). After its global withdrawal from routine immunization in 2016, outbreak response use has created a cycle of VDPV2 emergences that threaten eradication. We implemented a hierarchical model based on VP1 region genetic divergence, time, and location to attribute emergences to campaigns and identify risk factors. We found that a 10 percentage point increase in population immunity in children younger than 5 years at the campaign time and location corresponds to a 18.0% decrease (95% credible interval [CrI], 6.3%-28%) in per-campaign relative risk, and that campaign size is associated with emergence risk (relative risk scaling with population size to a power of 0.80; 95% CrI, .50-1.10). Our results imply how Sabin OPV2 can be used alongside the genetically stable but supply-limited novel OPV2 (listed for emergency use in November 2020) to minimize emergence risk.
No takes yet. Share an insight, caveat, or question.
Gray et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: